Cyramza (ramucirumab)

Frequently asked

Common questions about Cyramza's patent landscape

When will biosimilars enter the market for Cyramza?

Cyramza's foundational composition patent already expired (Mar 4, 2022), so the cliff window is open. The cliff closes Aug 21, 2037 when the last US lifecycle patent falls. Whether biosimilars have actually entered depends on the strength of secondary patents (formulations, methods of use, manufacturing) and whether settlements were reached — the Humira precedent saw biosimilars enter ~7 years past composition expiry under licensing agreements with AbbVie.

What's the difference between "cliff opens" and "cliff closes"?

Cliff opens (Mar 4, 2022) marks Cyramza's foundational composition patent expiry — the earliest theoretical date for biosimilar entry. Cliff closes (Aug 21, 2037) is when the last US patent in the thicket finally falls — after which the market has no patent-based barriers. The gap between these two dates is the lifecycle-extension window: secondary patents (formulations, methods of use, manufacturing) that can block biosimilars even after the composition patent has expired.

Why is Cyramza in the Purple Book?

Cyramza is regulated via the FDA biologic license application (BLA) pathway and listed in the FDA Purple Book (biologics). Biologics are not required to list patents with the FDA — the Purple Book does not include patent listings. The patents shown here are curated by TheraRadar via Google Patents BigQuery search of the sponsor (Eli Lilly and Company) and mechanism keywords, not pulled from an FDA list.

What's a patent family and why does it matter?

A patent family is a group of patent applications and grants worldwide that share the same priority filing (the earliest invention disclosure). One US patent often expands to 20–40+ filings across different jurisdictions — each grant in a different country protecting the same underlying invention. Cyramza has 4 families that resolve to 95 international documents across 30 countries. Families matter because biosimilar entry requires clearing patent barriers in each market separately — a US biosimilar launch is independent of EU or Japan launches.

How were these Cyramza patents identified?

Cyramza is a biologic, and the FDA's Purple Book does not include patent listings. TheraRadar identified these 4 patents via Google Patents BigQuery search using the sponsor (Eli Lilly and Company) plus mechanism-specific keywords. This is a curated thicket, not an authoritative FDA list. We then expand each patent to its full international family using the BigQuery patent family graph. Coverage is best-effort and may not capture every patent the sponsor holds.

What does the "Multiplier" stat mean?

The multiplier shows how many international patent documents exist for every US patent in Cyramza's thicket — calculated as 95 international documents ÷ 4 US patents = 24×. A high multiplier (>10×) indicates an aggressive global filing strategy — the sponsor has filed in many countries to maximize geographic protection. A low multiplier suggests the patent estate is US-centric, with limited international protection.